

Dartmouth College

Dartmouth Digital Commons

Dartmouth Scholarship

Faculty Work

10-27-2015

Mannitol Does Not Enhance Tobramycin Killing of *Pseudomonas aeruginosa* in a Cystic Fibrosis Model System of Biofilm Formation

Katherine E. Price
Dartmouth College

Giulia Orazi
Dartmouth College

Kathryn L. Ruoff
Dartmouth College

Wesley P. Hebert
Dartmouth College

George A. O'Toole
Dartmouth College

See next page for additional authors

Follow this and additional works at: <https://digitalcommons.dartmouth.edu/facoa>



Part of the [Medicine and Health Sciences Commons](#)

Dartmouth Digital Commons Citation

Price, Katherine E.; Orazi, Giulia; Ruoff, Kathryn L.; Hebert, Wesley P.; O'Toole, George A.; and Mastoridis, Paul, "Mannitol Does Not Enhance Tobramycin Killing of *Pseudomonas aeruginosa* in a Cystic Fibrosis Model System of Biofilm Formation" (2015). *Dartmouth Scholarship*. 2905.
<https://digitalcommons.dartmouth.edu/facoa/2905>

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Authors

Katherine E. Price, Giulia Orazi, Kathryn L. Ruoff, Wesley P. Hebert, George A. O'Toole, and Paul Mastoridis

RESEARCH ARTICLE

Mannitol Does Not Enhance Tobramycin Killing of *Pseudomonas aeruginosa* in a Cystic Fibrosis Model System of Biofilm Formation

Katherine E. Price¹, Giulia Orazi¹, Kathryn L. Ruoff¹, Wesley P. Hebert¹, George A. O'Toole^{1*}, Paul Mastoridis^{2*}

1 Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America, **2** Novartis Pharmaceutical Corporation, East Hanover, New Jersey, United States of America

* georgeo@dartmouth.edu (GAO); paul.mastoridis@novartis.com (PM)



OPEN ACCESS

Citation: Price KE, Orazi G, Ruoff KL, Hebert WP, O'Toole GA, Mastoridis P (2015) Mannitol Does Not Enhance Tobramycin Killing of *Pseudomonas aeruginosa* in a Cystic Fibrosis Model System of Biofilm Formation. PLoS ONE 10(10): e0141192. doi:10.1371/journal.pone.0141192

Editor: Read Pukkila-Worley, University of Massachusetts Medical School, UNITED STATES

Received: July 7, 2015

Accepted: October 5, 2015

Published: October 27, 2015

Copyright: © 2015 Price et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This work was supported by Novartis Pharmaceuticals (Joint collaboration between Novartis and Geisel School of Medicine at Dartmouth, Hanover, NH, US. S-code: TMB100C_S2241686 MA PLA 2014; <https://www.novartis.com/>) and by Cystic Fibrosis Foundation (Grant no. PRICE13F0; www.cff.org/). PM of Novartis had a role in study design, the decision to publish and preparation of manuscript but no role in data collection or analysis. Cystic Fibrosis Foundation had no role in study design, data

Abstract

Cystic Fibrosis (CF) is a human genetic disease that results in the accumulation of thick, sticky mucus in the airways, which results in chronic, life-long bacterial biofilm infections that are difficult to clear with antibiotics. *Pseudomonas aeruginosa* lung infection is correlated with worsening lung disease and *P. aeruginosa* transitions to an antibiotic tolerant state during chronic infections. Tobramycin is an aminoglycoside currently used to combat lung infections in individuals with CF. While tobramycin is effective at eradicating *P. aeruginosa* in the airways of young patients, it is unable to completely clear the chronic *P. aeruginosa* infections in older patients. A recent report showed that co-addition of tobramycin and mannitol enhanced killing of *P. aeruginosa* grown in vitro as a biofilm on an abiotic surface. Here we employed a model system of bacterial biofilms formed on the surface of CF-derived airway cells to determine if mannitol would enhance the antibacterial activity of tobramycin against *P. aeruginosa* grown on a more clinically relevant surface. Using this model system, which allows the growth of robust biofilms with high-level antibiotic tolerance analogous to in vivo biofilms, we were unable to find evidence for enhanced antibacterial activity of tobramycin with the addition of mannitol, supporting the observation that this type of co-treatment failed to reduce the *P. aeruginosa* bacterial load in a clinical setting.

Introduction

Cystic fibrosis (CF) is a human genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR). In the airways, defects in CFTR result in an accumulation of thick sticky mucus, which can become chronically infected with bacterial biofilms that are difficult to clear and are recalcitrant to antibiotic treatment. Of particular concern is infection with the Gram-negative bacterium *Pseudomonas aeruginosa*, as infection with *P. aeruginosa* is correlated with CF lung function decline and worsening disease. Lung infections are the primary cause of morbidity and mortality of individuals with cystic fibrosis despite the near-constant administration of antibiotics [1–3]. Therefore, there is a critical need to develop

collection and analysis, decision to publish, or preparation of manuscript.

Competing Interests: PM is an employee of Novartis Pharmaceutical Corporation, the manufacture of inhaled tobramycin. KEP, KLR, WPH and GAO declare no competing interests. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

new antibiotics, or alternatively, to develop compounds that render biofilms more sensitive to current therapies.

Several hypotheses explain the antibiotic tolerance of bacterial biofilms including physical barriers to antibiotic penetrance from extracellular matrix that biofilms produce [4, 5], the production of periplasmic glucans [6], slow growth [7] and/or the presence of metabolically inactive persister cells within a biofilm that are inherently tolerant to antibiotics [8–10]. In regard to the persister model, Rice and colleagues recently demonstrated a synergistic effect of tobramycin, the frontline CF maintenance therapy antibiotic, and mannitol versus *P. aeruginosa* grown in vitro as a biofilm on an abiotic surface [10]. The authors attribute this increase in tobramycin sensitivity to a stimulation of the persister cells from dormancy as had been previously described for *E. coli* [9].

Biofilms formed on abiotic surfaces (plastic or glass), while a relevant model for medical device implants, may not accurately represent the biofilms that form in the CF lung, as they may miss important contributions from the host, including the release of nutrients such as iron and the availability of a biotic substratum to facilitate bacterial colonization [11–14]. In this study, we tested if mannitol treatment would render *P. aeruginosa* more sensitive to tobramycin when grown as a biofilm on the surface of airway cells derived from a cystic fibrosis patient homozygous for the $\Delta F508$ allele of CFTR. *P. aeruginosa* grown in this model system recapitulates several key aspects of CF lung disease, including robust biofilm formation compared to biofilms formed on non-CF airways cells as well as high-level antibiotic tolerance of these biofilms [12, 13]. Based on our studies, we were unable to find any evidence for enhanced antibacterial activity of tobramycin with mannitol co-treatment on eight strains of *P. aeruginosa*, including five CF clinical isolates, using this model system of bacterial biofilm formation on CF airway cells. These results support the observation that a mannitol-tobramycin co-treatment does not reduce bacterial load in patients who have been co-administered [15] and highlight the differences in antibiotic tolerance of biofilms formed on biotic and abiotic surfaces.

Materials and Methods

Bacterial strains and growth conditions

Bacterial strains used in this study are listed in Table 1. *P. aeruginosa* strains were routinely cultured in lysogeny broth (LB) liquid medium shaking at 37°C or on LB agar incubated at 37°C. Minimum inhibitory concentration (MIC) of tobramycin for *P. aeruginosa* strains were measured using Biomerieux E-test strips according to manufacture's instructions.

Table 1. Strains used in this study.

| Strain number | Source | Tob MIC ($\mu\text{g/mL}$) ^a | Mucoid | Reference |
|----------------------|--|---|--------|-----------|
| <i>P. aeruginosa</i> | | | | |
| SMC232 | Laboratory strain, <i>P. aeruginosa</i> PA14 | 0.75 | No | [16] |
| SMC1585 | CF sputum isolate | 0.125 | Yes | [17] |
| SMC1587 | CF sputum isolate | 8.0 | No | [17] |
| SMC1595 | CF sputum isolate | 1.5 | No | [17] |
| SMC1596 | CF sputum isolate | 1.0 | No | [17] |
| SMC5450 | CF sputum isolate | 1.0 | Yes | [17] |
| SMC84 | <i>P. aeruginosa</i> PAO1 | 0.5 | No | [18] |
| SMC407 | <i>P. aeruginosa</i> FRD1 | 1.0 | Yes | [17, 19] |

^a Minimum inhibitory concentration of tobramycin for *P. aeruginosa* strains as measured by Biomerieux E-test strips according to manufacture's instructions.

Tissue culture cultivation

The cystic fibrosis bronchial epithelial (CFBE) cell line used in this study over expresses F508del-CFTR via stable lentiviral transfection of human bronchial epithelial cells [20] (CFBE41o⁺, isolated from a CF patient who was homozygous for Δ F508-CFTR mutation), which were originally immortalized and characterized by Gruenert and colleagues [21, 22]. CFBE cells were the generous gift of J.P. Clancy. IRB approval was not required for the use of this cell line. CFBE cells were cultivated as previously described [12, 13]. Briefly, CFBE cells were seeded into 24-well plates at 50,000 cells/well and fed every other day with minimal essential medium (MEM, Life Technologies) supplemented with 2 mM L-glutamine, 50 U/mL Penicillin, 50 μ g/mL Streptomycin, 2 μ g/mL Puromycin, 5 μ g/mL Plasmocin, and 10% Fetal Bovine Serum until confluent and had formed tight junctions [5–7 days].

Biofilm antibiotic assay on airway cells

Biofilm antibiotic assays were performed as previously described [12, 13]. Briefly, an overnight culture of *P. aeruginosa* was washed and resuspended in 1 mL of MEM. *P. aeruginosa* inoculum was prepared to an OD₆₀₀ of 0.05 ($\sim 5 \times 10^7$ CFUs/mL) in MEM supplemented with 2 mM L-glutamine. Next, 0.5 mL of the *P. aeruginosa* suspension was gently added to each well of CFBE cells that had been washed twice with MEM. Cultures were incubated one hour at 37°C, 5% CO₂. One hour post-inoculation, unattached cells were removed by aspiration and the medium was replaced with MEM supplemented with 2 mM L-glutamine and 0.4% arginine. Six hours post inoculation, the unattached bacteria were removed by aspiration to remove the planktonic fraction of bacteria; the biofilm fraction was washed once with MEM supplemented with 2 mM L-glutamine and 0.4% arginine and incubated with or without 8 μ g/mL tobramycin and/or 60 mM mannitol, as indicated, in MEM supplemented with 2 mM L-glutamine and 0.4% arginine. Twenty-one hours post-inoculation, planktonic fractions were removed. MEM was added to wells and the biofilms disrupted by scraping with a pipette tip. The biofilm-grown bacteria were serially diluted and then plated on LB and incubated overnight at 37°C. After overnight incubation, resulting colonies were counted and CFUs were determined. CFUs/well were log₁₀ transformed. Log₁₀ transformed data was used for all figures and statistical analyses.

Biofilm antibiotic assay on plastic

An overnight culture of *P. aeruginosa* was washed and resuspended in 1 mL of MEM. *P. aeruginosa* inoculum was prepared to an OD₆₀₀ of 0.05 ($\sim 5 \times 10^7$ CFUs/mL) in MEM supplemented with 2 mM L-glutamine. Next, 0.1 mL of the *P. aeruginosa* suspension was gently added to each well of a 96-well culture plate. Cultures were incubated one hour at 37°C, 5% CO₂. One hour post-inoculation, unattached cells were removed and the medium was replaced with MEM supplemented with 2 mM L-glutamine and 0.4% arginine. Six hours post inoculation, the unattached bacteria were removed and the biofilm fraction was incubated with or without 80 μ g/mL tobramycin and/or 60 mM mannitol in MEM supplemented with 2 mM L-glutamine and 0.4% arginine. Twenty-one hours post-inoculation, planktonic fractions were removed. MEM was added to wells and biofilms were disrupted using a solid pin multi-blot replicator. The biofilm-grown bacteria were serially diluted and then plated on LB and incubated overnight at 37°C. After overnight incubation, resulting colonies were counted and CFUs were determined. CFUs/well were log₁₀ transformed. Log₁₀ transformed data was used for all figures and statistical analyses.

Cytotoxicity Assay

Cytotoxicity was measured as fraction of lactate dehydrogenase (LDH) release using the CytoTox 96 Non-radioactive Cytotoxicity Kit (Promega) according to the manufacturer's instructions. CFBE cells were incubated with 0, 40 or 60 mM mannitol (dissolved in MEM) for 24 hours at 37°C, 5% CO₂. Supernatants were collected and used in the CytoTox 96 Non-radioactive Cytotoxicity Kit. Cells treated with Triton X-100 detergent served as the total lysis control. Fraction cytotoxicity was determined by dividing the absorbance at 450 nm of each sample (OD₄₅₀) by the OD₄₅₀ of the total lysis control.

Results

Mannitol co-treatment does not increase the susceptibility of a laboratory strain of *P. aeruginosa* to tobramycin

To test the hypothesis that mannitol would increase the antibacterial activity of tobramycin on CF airway cell-grown biofilms of *P. aeruginosa*, we first measured the cytotoxic effect of mannitol on CF airways cells to ensure that the dose of mannitol used in subsequent studies did not damage the host cells. In these studies, CF-derived bronchial epithelial (CFBE) cells, which are homozygous for the $\Delta F508$ mutation in CFTR, were used as the substratum to grow the *P. aeruginosa* biofilms. To assess cytotoxicity of mannitol, CFBE cells were incubated with increasing concentrations of mannitol, or medium alone as a control, for 24 hours. Supernatants were collected, bacteria were removed by centrifugation and clarified supernatants were used to determine cytotoxicity, which was expressed as the fraction of the cytoplasmic enzyme LDH released, using a colorimetric assay. LDH activity was normalized to a total lysis control, set at 1.0, wherein the host cells were treated with Triton-X 100, a detergent used to burst cells open. Treatment with 40 mM or 60 mM mannitol, which falls within the range of concentrations used in previous studies with abiotic biofilms [10], resulted in low cytotoxicity (less than 20% of total lysis), comparable to treatment with tissue culture medium alone (Fig 1A). Because the higher dose had minimal cytotoxicity, we used 60 mM mannitol in all subsequent assays.

To test if mannitol treatment could sensitize *P. aeruginosa* to tobramycin treatment in the context of a biofilm formed on the surface of airway cells, we established *P. aeruginosa* strain PA14 biofilms on the surface of CF airway cells as previously described [12, 13]. Biofilms were established for six hours before treatment with medium, tobramycin, mannitol or co-treatment with tobramycin and mannitol. After fifteen hours of treatment, the viability of *P. aeruginosa* growing as a biofilm was determined by colony counts. Treatment with 60 mM mannitol alone resulted in similar viability to treatment with medium alone. Treatment with 8 μ g/mL of tobramycin resulted in a 3.3-log₁₀ reduction in viability of biofilm grown bacteria. Co-treatment of *P. aeruginosa* grown as a biofilm on CFBE cells with 8 μ g/mL of tobramycin and 60 mM mannitol resulted in a 2.9-log₁₀ reduction in viability; a difference which is not statistically significant from treatment with tobramycin alone, suggesting that mannitol does not sensitize *P. aeruginosa* to tobramycin (Fig 1B).

Mannitol co-treatment does not increase the susceptibility of CF clinical isolates of *P. aeruginosa* to tobramycin

The laboratory strain *P. aeruginosa* PA14, while a recent isolate of this microbe, was obtained from a burn wound and may not accurately reflect the strains of *P. aeruginosa* found in the airways of individuals with CF. We therefore examined the effects of mannitol co-treatment with tobramycin on 5 clinical strains isolated from sputum of individuals with CF (Table 1). These strains exhibited a range of tobramycin resistance and mucoidy as previously characterized




Fig 1. Mannitol does not sensitize non-mucoid, laboratory strain *P. aeruginosa* PA14 to tobramycin.
A. Mannitol is minimally cytotoxic to CFBE cells. Normalized cytotoxicity as measured by fraction of LDH release. Cytotoxicity was measured after 24 hours of treatment with 0, 40 or 60 mM mannitol as indicated. Cells lysed with Triton X-100 served as a control to determine total lysis. Columns indicate mean of at least three biological replicates, error bars indicate standard deviation (S.D.). **, $P < 0.01$, comparison of indicated sample to total lysis control by ordinary one-way ANOVA with Tukey's post test for multiple comparisons. B. Viability of *P. aeruginosa* PA14 grown as a biofilm on CFBE cells after treatment with 0 µg/mL tobramycin (open bars), 8 µg/mL tobramycin (hatched bars), 0 mM mannitol (white bars), 60 mM mannitol (gray bars) or co-treatment with 8 µg/mL tobramycin and 60 mM mannitol, as indicated. Columns indicate mean of at least three biological replicates, error bars indicate S.D. ***, $P < 0.001$ by ordinary one-way ANOVA with Tukey's post test for multiple comparisons. There is no significant difference between *P. aeruginosa* PA14 treated with tobramycin +/- mannitol.

doi:10.1371/journal.pone.0141192.g001

[17]. Strains SMC1585 and 5450 are mucoid, while strains SMC1587, 1595 and 1596 are non-mucoid; the tobramycin MIC for planktonically grown cultures of these strains is shown in Table 1.

There was no reduction of *P. aeruginosa* viability from mannitol treatment alone compared to treatment with medium alone for any of the clinical isolates tested (Fig 2). Additionally, there was no reduction of *P. aeruginosa* viability in biofilms co-treated with mannitol and tobramycin (at 8 µg/mL, the same concentration tested for the laboratory isolate) compared to treatment with tobramycin alone (Fig 2A). These results suggest that mannitol does not sensitize *P. aeruginosa* isolated from the airways of individuals with CF to tobramycin when grown as a biofilm on CF airway cells.

As an additional control, we also investigated the impact of mannitol on biofilms of *P. aeruginosa* PAO1 (a lab strain) and *P. aeruginosa* FRD1 (a clinical mucoid strain) treated with tobramycin. Mannitol did not enhance tobramycin-mediated killing of either of these strains (Fig 2B). Finally, we replicated the original finding of Rice and colleagues [10]. As was originally reported, when the biofilm of *P. aeruginosa* PAO1 was grown on plastic, the addition of mannitol enhanced tobramycin-mediated killing by ~100-fold (Fig 2C). It is important to note




Fig 2. Mannitol does not sensitize *P. aeruginosa* clinical isolates grown as biofilms on CF airway cells to tobramycin. A. Viability of *P. aeruginosa* clinical isolates grown as biofilms on CFBE cells and treated with 0 µg/mL tobramycin (open bars), 8 µg/mL tobramycin (hatched bars), 0 mM mannitol (white bars), 60 mM mannitol (gray bars) or co-treatment with 8 µg/mL tobramycin and 60 mM mannitol, as indicated. Columns indicate mean of at least three biological replicates, error bars indicate S.D. **, $P < 0.01$ by ordinary one-way ANOVA with Tukey's post test for multiple comparisons. B. The viability of strains *P. aeruginosa* PAO1 (left) and FRD1 (right) as biofilms on CFBE cells and treated with 0 µg/mL tobramycin (open bars), 8 µg/mL tobramycin (hatched bars), 0 mM mannitol (white bars), 60 mM mannitol (gray bars) or co-treatment with 8 µg/mL tobramycin and 60 mM mannitol, as indicated. **, $P < 0.01$ or ***, $P < 0.001$ by ordinary one-way ANOVA with Tukey's post test for multiple comparisons. ns, not significant compared to tobramycin treatment in the absence of mannitol. C. The viability of strain *P. aeruginosa* PAO1 as a biofilm on plastic and treated with 0 µg/mL tobramycin (open bars), 80 µg/mL tobramycin (hatched bars), 0 mM mannitol (white bars), 60 mM mannitol (gray bars) or co-treatment with 80 µg/mL tobramycin and 60 mM mannitol, as indicated. *, $P < 0.05$ compared to treatment with 80 µg/mL tobramycin with no mannitol. **, $P < 0.01$ or ***, $P < 0.001$ by ordinary one-way ANOVA with Tukey's post test for multiple comparisons.

doi:10.1371/journal.pone.0141192.g002

that while in our experiments we saw substantially more killing of *P. aeruginosa* PAO1 treated with tobramycin alone than was observed by Rice, et al. [10] we still observed the originally reported mannitol-enhanced killing.

Discussion

The bacteria that chronically infect the lungs of individuals with CF are recalcitrant to antibiotics. One hypothesis for this tolerance to treatment is that the bacteria are in a metabolically dormant state and are therefore intrinsically resistant to antibiotic pressure [8]. Because this tolerance is not genetically encoded, if these cells could be brought out of dormancy, they would then be sensitive to antibiotic killing. Such examples have been shown in *E. coli* [9] and in *P. aeruginosa* [10]. In the case of *P. aeruginosa*, a sub-set of strains of this microbe (strains PAO1 and FRD) grown as biofilms formed on an abiotic (plastic) surface were approximately 1000-fold more sensitive to tobramycin treatment with co-administration of mannitol and tobramycin. We replicated that finding here with a biofilm of *P. aeruginosa* PAO1 grown on plastic. However, an additional clinical isolate 18A was resistant to tobramycin, and co-administration of mannitol and tobramycin did not sensitize this strain, suggesting that tobramycin sensitization by mannitol is strain specific and is not generalizable.

To address whether the synergy of mannitol and tobramycin might be relevant to a CF patient population, we used our in vitro model system of bacterial biofilm formation on CF airway cells to assess whether this synergy also occurs on a more clinically relevant surface. *P. aeruginosa* grown in our model system recapitulate several key aspects of chronic biofilm formation, including formation of biofilm-like microcolonies, expression of genes associated with biofilm growth, induction of quorum sensing, the requirement for genes necessary for biofilm formation on abiotic surfaces and, of clinical importance, high-level antibiotic tolerance consistent with biofilms in clinical settings [12, 13]. Using this system, we were unable to recapitulate the sensitization effect that mannitol gave to tobramycin treated biofilms grown on plastic. This absence of synergy held true for the lab strains *P. aeruginosa* PA14 and PAO1, the well-characterized mucoid clinical isolate *P. aeruginosa* FRD1 as well as five other clinical strains of *P. aeruginosa* isolated from individuals with CF, including strains showing planktonic tobramycin resistance as well as mucoid and non-mucoid strains.

Mannitol is currently utilized as a therapeutic that hydrates mucus allowing for increased mucociliary and cough clearance of retained secretions in the airways of individuals with CF [15, 23]. Our model system does not produce mucus, therefore we cannot test the effect that mucus viscosity/ hydration has on tobramycin efficacy. It is formally possible that better hydration of the airways may allow better penetrance and therefore better effectiveness of antibiotics. However, in the clinical trial, no change in *P. aeruginosa* load was observed in patients given mannitol versus placebo control despite maintaining their current CF therapies including inhaled antibiotics [15], supporting our findings that tobramycin and mannitol do not synergize in the treatment of *P. aeruginosa* biofilms formed on airway cells.

Experiments presented here suggest that the mechanism of action of mannitol via stimulation of *P. aeruginosa* out of a dormant state and into metabolically active one that is sensitive to tobramycin, as suggested by Rice *et al.* [10], is unlikely to be occurring in biofilms formed on biotic surfaces. Additionally, our results illustrate that biofilms grown on biotic surfaces are distinct from biofilms grown on plastic, as has been previously reported [11–13] and highlights the cost and time savings achieved by using biofilms formed on biotic surfaces as an important tool in preclinical studies for drug discovery.

Author Contributions

Conceived and designed the experiments: PM GAO KEP. Performed the experiments: KLR WPH GO. Analyzed the data: KLR KEP GAO GO. Contributed reagents/materials/analysis tools: GAO. Wrote the paper: KEP GAO PM.

References

1. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. *Clin Microbiol Rev*. 2002 Apr; 15(2):194–222. PMID: [11932230](#). Pubmed Central PMCID: 118069. Epub 2002/04/05. eng.
2. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. *J Cyst Fibros*. 2005 Aug; 4 Suppl 2:3–5. PMID: [15970469](#). Epub 2005/06/23. eng.
3. Costerton JW. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. *Trends Microbiol*. 2001 Feb; 9(2):50–2. PMID: [11173226](#). Epub 2001/02/15. eng.
4. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. *Clin Microbiol Rev*. 2002 Apr; 15(2):167–93. PMID: [11932229](#). Pubmed Central PMCID: 118068.
5. Suci PA, Mittelman MW, Yu FP, Geesey GG. Investigation of ciprofloxacin penetration into *Pseudomonas aeruginosa* biofilms. *Antimicrob Agents Chemother*. 1994 Sep; 38(9):2125–33. PMID: [7811031](#). Pubmed Central PMCID: 284696.
6. Mah TF, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. A genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature*. 2003 Nov 20; 426(6964):306–10. PMID: [14628055](#).
7. Anwar H, Strap JL, Chen K, Costerton JW. Dynamic interactions of biofilms of mucoid *Pseudomonas aeruginosa* with tobramycin and piperacillin. *Antimicrob Agents Chemother*. 1992 Jun; 36(6):1208–14. PMID: [1416820](#). Pubmed Central PMCID: 190319.
8. Lewis K. Persister cells and the riddle of biofilm survival. *Biochemistry Biokhimiia*. 2005 Feb; 70(2):267–74. PMID: [15807669](#).
9. Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. *Nature*. 2011 May 12; 473(7346):216–20. PMID: [21562562](#). Pubmed Central PMCID: 3145328. doi: [10.1038/nature10069](#)
10. Barraud N, Buson A, Jarolimek W, Rice SA. Mannitol enhances antibiotic sensitivity of persister bacteria in *Pseudomonas aeruginosa* biofilms. *PLoS One*. 2013; 8(12):e84220. PMID: [24349568](#). Pubmed Central PMCID: 3862834. doi: [10.1371/journal.pone.0084220](#)
11. Tran CS, Rangel SM, Almblad H, Kierbel A, Givskov M, Tolker-Nielsen T, et al. The *Pseudomonas aeruginosa* type III translocon is required for biofilm formation at the epithelial barrier. *PLoS Pathog*. 2014 Nov; 10(11):e1004479. PMID: [25375398](#). Pubmed Central PMCID: 4223071. doi: [10.1371/journal.ppat.1004479](#)
12. Moreau-Marquis S, Bomberger JM, Anderson GG, Swiatecka-Urban A, Ye S, O'Toole GA, et al. The DeltaF508-CFTR mutation results in increased biofilm formation by *Pseudomonas aeruginosa* by increasing iron availability. *Am J Physiol Lung Cell Mol Physiol*. 2008 Jul; 295(1):L25–37. PMID: [18359885](#). Pubmed Central PMCID: 2494796. Epub 2008/03/25. eng. doi: [10.1152/ajplung.00391.2007](#)
13. Anderson GG, Moreau-Marquis S, Stanton BA, O'Toole GA. In vitro analysis of tobramycin-treated *Pseudomonas aeruginosa* biofilms on cystic fibrosis-derived airway epithelial cells. *Infect Immun*. 2008 Apr; 76(4):1423–33. PMID: [18212077](#). Pubmed Central PMCID: 2292855. Epub 2008/01/24. eng. doi: [10.1128/IAI.01373-07](#)
14. Moreau-Marquis S, Stanton BA, O'Toole GA. *Pseudomonas aeruginosa* biofilm formation in the cystic fibrosis airway. *Pulm Pharmacol Ther*. 2008 Aug; 21(4):595–9. PMID: [18234534](#). Pubmed Central PMCID: 2542406. Epub 2008/02/01. eng. doi: [10.1016/j.pupt.2007.12.001](#)
15. Bilton D, Bellon G, Charlton B, Cooper P, De Boeck K, Flume PA, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. *J Cyst Fibros*. 2013 Jul; 12(4):367–76. PMID: [23234802](#). doi: [10.1016/j.jcf.2012.11.002](#)
16. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. Common virulence factors for bacterial pathogenicity in plants and animals. *Science*. 1995 Jun 30; 268(5219):1899–902. PMID: [7604262](#).
17. Yu Q, Griffin EF, Moreau-Marquis S, Schwartzman JD, Stanton BA, O'Toole GA. In vitro evaluation of tobramycin and aztreonam versus *Pseudomonas aeruginosa* biofilms on cystic fibrosis-derived human airway epithelial cells. *J Antimicrob Chemother*. 2012 Jul 26; 67(11):2673–81. PMID: [22843834](#). Epub 2012/07/31. Eng. doi: [10.1093/jac/dks296](#)

18. Holloway BW. Genetic recombination in *Pseudomonas aeruginosa*. J Gen Microbiol. 1955 Dec; 13 (3):572–81. PMID: [13278508](#).
19. Garrett ES, Perlegas D, Wozniak DJ. Negative control of flagellum synthesis in *Pseudomonas aeruginosa* is modulated by the alternative sigma factor AlgT (AlgU). J Bacteriol. 1999 Dec; 181(23):7401–4. PMID: [10572149](#). Pubmed Central PMCID: 103708.
20. Hentchel-Franks K, Lozano D, Eubanks-Tarn V, Cobb B, Fan L, Oster R, et al. Activation of airway Cl-secretion in human subjects by adenosine. Am J Respir Cell Mol Biol. 2004 Aug; 31(2):140–6. PMID: [15039139](#).
21. Cozens AL, Yezzi MJ, Kunzelmann K, Ohri T, Chin L, Eng K, et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol. 1994 Jan; 10(1):38–47. PMID: [7507342](#).
22. Bruscia E, Sangiuolo F, Sinibaldi P, Goncz KK, Novelli G, Gruenert DC. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther. 2002 Jun; 9(11):683–5. PMID: [12032687](#).
23. Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J. 2011 Nov; 38(5):1071–80. PMID: [21478216](#). doi: [10.1183/09031936.00187510](#)